Mirta Grifman

Mirta Grifman has extensive work experience in the pharmaceutical industry. Mirta is currently employed at Biosplice Therapeutics, where they hold the position of Vice President, Clinical Development and External Innovation since December 2022. Prior to this, they served as Vice President, Medical Affairs from March 2022 to December 2022, Executive Director, Medical Affairs from March 2020 to March 2022, and Senior Director, Medical Affairs from October 2017 to March 2020.

Before joining Biosplice Therapeutics, Mirta worked at GSK as a Director of Medical Affairs from April 2014 to October 2017. Mirta took a career break from April 2013 to March 2014.

Prior to GSK, Mirta worked at TEVA PHARMA as the Director of Medical Science Liaisons (MSLs) from December 2011 to January 2013. Before TEVA PHARMA, they were employed at Cephalon Inc (acquired by Teva Pharma) where they served as an Associate Director of Medical Science Liaisons (MSLs) from May 2008 to December 2011 and as a Medical Science Liaison (MSL) from June 2007 to May 2008.

Mirta also worked at Novartis/SOS as a Medical Science Liaison (MSL) from September 2006 to June 2007, and at the Canadian Consulate as a Business Development Officer from September 2005 to September 2006. Mirta started their career at Immusol, where they held the positions of Senior Scientist, Business Development from November 2004 to August 2005, and Scientist and Group Leader from June 2001 to November 2004.

Mirta Grifman's education history begins in 1987 with a Bachelor of Science in Biology from The Hebrew University of Jerusalem. Mirta then pursued a Master of Science in Microbiology from the same institution, which they obtained in 1993. Following this, Mirta Grifman furthered their education at The Hebrew University of Jerusalem and completed their Ph.D. in Molecular Biology and Biochemistry in 1998. During the years 1998 to 2001, Mirta Grifman attended The Salk Institute for Biological Studies, although no specific degree or field of study information is provided for this period. Additionally, Mirta Grifman obtained the certification of GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) from the CITI Program in December 2022.